This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mortality, Cost And Health Outcomes Of Total Knee Arthroplasty In Medicare Patients

MENLO PARK, Calif., March 27, 2013 /PRNewswire/ -- Exponent, Inc. (NASDAQ: EXPO), is pleased to announce that its scientists have recently had their study on mortality, cost, and health outcomes of total knee arthroplasty in Medicare patients published online in the Journal of Arthroplasty. 

In the study of Medicare records, Exponent scientists examined the effects of joint replacement among nearly 135,000 patients with new diagnoses of osteoarthritis of the knee from 1997 to 2009. About 54,000 opted for knee replacement; 81,000 did not.  Three years after diagnosis, the knee replacement patients had an 11 percent lower risk of heart failure.  And after seven years, their risk of dying for any reason was 50 percent lower.

The theory behind knee replacement, said the study's lead author, Dr. Scott Lovald, Senior Associate at Exponent, is that treating this degenerative condition will allow a return to normal activity and ultimately improve overall quality of life.  "At the end of the day, we're trying to figure out if quantity of life increases as well," he added, noting that the team was conducting a similar review of Medicare data on the long-term benefits of hip replacement surgery.

"These patients had improved survivorship and reduced risk for cardiovascular conditions." "For an incremental cost of less than $3,000 per year, total knee replacement may reduce the risk of mortality by half."

A subsequent review of Medicare data on long term benefits of hip replacement surgery is showing that Total Hip Replacement  (THR), or hip replacement, is associated with reduced mortality, heart failure, depression and diabetes rates in Medicare patients with osteoarthritis. The results of the study were presented at the 2013 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) held in Chicago March 19-22nd. 

View the full abstract here:

Exponent, Inc. is a multidisciplinary organization of scientists, physicians, engineers, and business consultants performing in-depth investigations in more than 90 technical disciplines.  The company investigates and analyzes failures and accidents to determine their causes and prevention and evaluates and solves complex human health and environmental issues.  Exponent is certified to ISO 9001.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%
TSLA $247.54 -0.07%
YHOO $36.59 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs